Modality
Fusion Protein
MOA
KRASG12Ci
Target
Tau
Pathway
Neuroinflam
MigraineOCDSLE
Development Pipeline
Preclinical
Mar 2017
→ Mar 2029
PreclinicalCurrent
NCT04845304
258 pts·Migraine
2018-12→2029-03·Terminated
NCT07172122
2,678 pts·SLE
2017-03→2029-03·Completed
2,936 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-03-082.9y awayInterim· SLE
2029-03-153.0y awayInterim· Migraine
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Preclinical
Complet…
Preclinical
Termina…
Catalysts
Interim
2029-03-08 · 2.9y away
SLE
Interim
2029-03-15 · 3.0y away
Migraine
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04845304 | Preclinical | Migraine | Terminated | 258 | UPDRS |
| NCT07172122 | Preclinical | SLE | Completed | 2678 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ |